Bukwang Pharmaceutical : IR Fact Book 4Q23 (Reviewed by External Auditor)

Bukwang Pharmaceutical

Fact Book 2023

Disclaimer

This presentation contains forward-looking statements about Bukwang Pharmaceutical Co., Ltd. Such statements are related to incidents of the future and not of the past, and include business status and financial performance that the company predicts for the future. The predictions and estimations have

inherent uncertainties and risks, so please keep in mind that the company's

actual future performance may differ from the estimated performance. The inherent uncertainties and risks include changes in relevant rules and regulations, changes in general business environment and fluctuations in the financial market.

01 Company overview

		Company history
		Shareholders'
		status & Stock
		Price
		VISION
		Growth Strategy
INDEX	& Motives
04	Profit and Loss of
fourth Quarter in
	Business	2023
	business outlook
		2023 Annual
		Consolidated
		Performance
		Summary
		Key issues and
	updates	ETC Prescription
	management
		Results
		Business Goals
		for the Year 2024
		Sustainable

02	R&D Strategy	03 R&DMain Pipeline
R&D	Open Innovation	Pipeline	Latuda
JaguAhR Therapeutics
	Main R&D activities

Global Network	MLR-1023
JM-010
Contera Pharma
Protekt Therapeutics
Investment Portfolio

05	Summary of
Consolidated Financial
Position
Appendix	Joint Management
	with OCI

Introduction

4

Company overview

CEO	Woo-hyun Lee
Establishment	October 17th, 1960
Business	Manufacturing and sales of pharmaceuticals
	and non-pharmaceutical products
shares	71,063,049 shares
Personnel	611

*As of December 2023

Headquarter	Bukwang Pharmaceutical Co., Ltd.		Facilities	R&D Center		Facilities	Ansan Manufacturing Plant
Location	7, Sangdo-ro,Dongjak-gu, Seoul
	Location	7, Sangdo-ro,Dongjak-gu, Seoul		Location	47, Neungan-ro,Danwon-gu,
							Ansan, Gyeonggi Province

5

Company history

1960	1985	1988	1993
Establishment	The first approval	Listed on KOSPI	Establishment of
	of K.G.M.P in Korea		Central Research Institute

2016	2015	2014	2006
Establishment of	Establishment of	Acquisition of Contera Pharma	Levovir®
New Drug
Dyna therapeutics	Bukwang Medica	based in Copenhagen,
Approval
		Denmark

2018	2022	2023	2024
First in the	Joint management	Acquisition
pharmaceutical industry
system with OCI	of Protekt Therapeutics
Obtaining ISO45001

6

Shareholders' status & Stock Price

Shareholders' status

71,063,049	4,335
shares	billion won

10.9	OCI holdings

9.93 Dong-Yeon Kim

Chang-Su Jeong

Issued shares	Market		8.51	National Pension Service
Capitalization		Foreigner
	60.64
7billion won	4.33%	2.02
	Treasury stock
	4.33
Average daily	Foreign ownership
	3.67	Others
trading volume	Percentage
Stock price trend				*As of December 2023
(January 13, 2023 - January 15, 2024)

KOSPI Pharmaceutical

Bukwang Pharmaceutical

Mar 2023

Jun 2023

Sep 2023

Dec 2023

7

VISION

• Bukwang Pharmaceutical aims to become a global pharmaceutical and biotech company based on the management philosophy of 'contributing to the stability of drug supply and society through the production of excellent pharmaceuticals
• Bukwang Pharmaceutical is increasing its corporate value through enhancing competitiveness in its main business area of new drug development and expanding synergies

Dyna Therapeutics

8

Growth Strategy & Motives

Global open innovation in R&D

Global R&D Experience

• Development of Hepatitis B Antiviral Agents
• Incrementally modified drug for diabetic neuropathy
• Development of anti-cancer drugs for stomach cancer and diabetes treatments

A variety of pipelines

• Business models
• CNS : dyskinesia in Parkinson's disease,
  Parkinson's disease, Alzheimer's disease, etc
• Anti-cancerdrugs: Immune-oncology, prostate cancer, etc

Investment Portfolio

• Various investment portfolio including Subsidiaries, Joint Ventures, Research Collaborations, Equity Investments, Indirect Investments, etc

R&D

Investment

Focus

CNS

Oncology

Diverse and distinctive

company portfolio

Bukwang	Growth of consumer health business
Medica
Contera	Positive outcome from ongoing
clinical study for JM-010
Pharma
Novel therapy from RNA platform
JaguAhr	L/O or acquisition of the company
after CD nomination
Protekt	L/O or acquisition of the company
after CD nomination

9

Major subsidiaries and R&D

10